Table 2

Results of retreatment according to baseline features and regimens administered

End of treatment responseSustained response
Biochemical (% (No))Complete (% (No))Biochemical (% (No))Complete (% (No))
HCV, hepatitis C virus; IFN, α interferon; MU, mega units.
All patients46.6 (271/581)38.7 (206/532)18.7 (109/581)15.7 (88/559)
Cirrhosis
    Present29.6 (19/64)27.5 (16/58)14 (9/64)12.5 (8/64)
    Absent48.7 (252/517)40 (180/474)19.3 (100/517)16.1 (80/495)
    p Value 0.004 0.0650.30 0.44
Genotype
    145.6 (142/311)30.4 (92/302)15.1 (47/311)14.4 (43/297)
    Non-147.7 (129/270)49.5 (114/230)22.9 (62/270)17.1 (45/262)
    p Value 0.60 0.001 0.016 0.38
HCV-RNA
    ≥2×106 copies/ml30.8 (21/68)30 (18/60)22 (15/68)17.6 (12/68)
    <2×106 copies/ml49.5 (169/341)37.3 (115/308)18.1 (62/341)16.3 (55/336)
    p Value 0.005 0.27 0.45 0.79
IFN retreatment regimens
    Standard dose (234 MU)39.2 (33/84)31.6 (25/79) 8.3 (7/84) 6.1 (5/82)
    Medium dose (>234–468 MU)46.3 (133/287)34 (91/267)15.3 (44/287)13.2 (36/272)
    High dose (>468 MU)50 (105/210)48.3 (90/186)27.6 (58/210)22.9 (47/205)
    p Value 0.24 0.003 0.001 0.001
Length of retreatment
    6 months44 (99/225)41.2 (83/201)11.1 (25/225)10.1 (21/208)
    12 months48.3 (172/356)58.3 (193/331)23.6 (84/356)19 (67/351)
    p Value 0.31 0.001 0.001 0.005
1st→2nd IFN course
    Standard→standard38.4 (20/52)39.5 (19/48)13.4 (7/52) 9.6 (5/52)
    Standard→medium/high49.5 (164/331)39.5 (121/306)21.7 (72/331)17.2 (55/319)
    Medium/high→standard40.6 (13/32)19.3 (6/31) 0 (0/32) 0 (0/30)
    Medium/high→medium/high44.5 (74/166)40.8 (60/147)18 (30/166)17.7 (28/158)
    p Value 0.35 0.15 0.016 0.044
Type of IFN for retreatment
    Recombinant α2b46.7 (256/548)52.3 (261/499)18.8 (103/548)15.5 (82/526)
    Leucocytic αN-345.4 (15/33)45.4 (15/33)18.1 (6/33)18.1 (6/33)
    p Value 0.88 0.44 0.93 0.69